By Ahmed El-Medany
Presented at ESC 2021 by Dr. Judit Simon, of the Heart and Vascular Centre, Semmelweis University, Budapest, Hungary; this large study included 468,629 UK Biobank participants with no known cardiac history (mean age, 56 years; 56% women; median follow-up, 11 years).
Participants were stratified into 3 groups based on their coffee habits: none (did not consume coffee on a regular basis, 22.1%), light-to-moderate (0.5 to 3 cups/day, 58.4%), and high (more than 3 cups/day, 19.5%).
After adjustment for all potential cardiovascular (CV) risk factors, light-to-moderate coffee consumption was associated with lower risk for all-cause death (HR = 0.88; 95% CI, 0.83-0.92; P < .001), CV death (HR = 0.83; 95% CI, 0.74-0.94; P = .006), and incident stroke (HR = 0.79; 95% CI, 0.63-0.99; P = .037) compared with individuals that did not drink coffee.
During a press conference, Simon stated: ‘The observed benefits might be partly explained by positive alterations in cardiac structure and function as assessed by standard cardiac magnetic resonance imaging.
Abstract title: Association of daily coffee consumption with cardiovascular health – Results from the UK Biobank.
Press conference: “Heart health made easy” on Thursday 26 August from 17:00 to 18:00 CEST.
